Order Rejuran® I for Clinics

Rejuran® I is a polynucleotide injectable developed for professional use in the delicate periorbital area. Licensed clinics, med spas, and healthcare professionals can order Rejuran I as a 1ml syringe for under-eye and periocular treatment workflows. Its low-viscosity profile supports controlled microinjection or soft cannula placement where thin skin requires careful spread and conservative technique.

This preparation is stocked by aesthetic practices that offer skin-quality treatments around the eyes. Rejuran I injectable is commonly positioned as a PN-based skin booster rather than a volumizing hyaluronic acid filler, so clinics should match it to protocols focused on texture, hydration balance, elasticity, and tissue-support planning.

Rejuran I Price, Pack Details, and Clinic Ordering

Current prices and quantity breaks are shown on this page, and licensed clinics can order as a guest or with an account.

The supplied unit is a single-use Rejuran I 1ml syringe. This compact format fits under-eye treatment trays, procedure carts, and appointment blocks where one sealed syringe is assigned to one treatment session. Lot number and expiration details should be recorded according to clinic policy before administration.

For practices building a broader injectable skin-quality program, the skin boosters category can help teams organize PN and related regenerative-style options by treatment area, viscosity, and workflow fit. Choose products according to injector training, anatomy knowledge, and the clinic’s approved protocols.

What Rejuran I Is and How It Works

Rejuran I is an injectable polynucleotide solution designed for the periocular zone, including the thin skin around the lower eyelid region. Polynucleotides are purified DNA fragments that are used in aesthetic medicine to support the skin environment, including fibroblast activity and extracellular matrix balance.

In practice, clinics use this class to support tissue renewal, hydration balance, and smoother-looking skin texture. Rejuran I for eyes is selected when fine placement, controlled spread, and a low-viscosity injectable are priorities. It is not used as a direct substitute for a structural filler when the treatment goal is mechanical volume replacement.

The formulation is described as salmon DNA-derived PN in a sterile injectable solution. Because the periorbital area has thin skin, visible vascular structures, and limited tolerance for swelling or irregular placement, administration should remain within professional training and local practice standards.

Professional Applications Around the Eyes

Clinics commonly use Rejuran I under eye within periocular rejuvenation plans. Typical treatment workflows may include microdroplet placement along the infraorbital region, conservative placement near tear-trough-adjacent zones, or soft cannula distribution where the injector’s technique and anatomy assessment support that approach.

Some practices schedule PN injectables alongside energy-based devices, resurfacing, microneedling, or topical skincare programs in staged visits. When used this way, the product functions as a texture-focused adjunct rather than a stand-alone solution for every concern around the eyes. Patient selection, timing between procedures, and post-treatment instructions should follow the clinic’s established protocols.

Rejuran I eye injection services are often considered for fine crepiness, uneven skin quality, and maintenance-oriented periocular plans. The product’s low-viscosity character is useful when shallow placement and even spread are needed, but it does not remove the need for careful mapping, conservative volumes, and avoidance of unsafe planes.

Key Features for Treatment-Room Use

• PN formulation: Polynucleotides support skin-quality programs that focus on tissue repair processes and dermal balance.
• Periocular fit: The preparation is designed for delicate under-eye and surrounding eye-area workflows.
• Low viscosity: A fluid texture supports controlled microinjection patterns in thin skin.
• Single-use format: Each Rejuran I 1ml syringe is intended for one patient session.
• Sterile injectable supply: Use only when packaging integrity is intact and professional administration is appropriate.
• Traceable labeling: Lot and expiry information support inventory logs and procedure documentation.
• Protocol flexibility: The product can fit needle or microcannula techniques when selected by trained injectors.

Benefits in Clinic Workflows

Rejuran I fits appointment menus that separate skin-quality treatment from filler-based contouring. This distinction helps consultation teams explain why a PN injectable may be selected for texture and elasticity support, while a different product may be used when the goal is projection, contour, or deep structural correction.

The 1ml syringe format helps practices plan treatment-room setup with minimal handling complexity. A sealed single-use unit reduces cross-use risk, simplifies tray preparation, and supports clear documentation. Staff should follow facility policy for sharps disposal and any unused material after the session.

For shallow, controlled delivery, some clinics pair periocular boosters with compatible microinjection accessories. Rejuran skin booster clinical reading may also help staff align product education with PN treatment positioning, while hands-on technique decisions remain the responsibility of qualified clinicians.

Composition and Ingredients

Active ingredient: Polynucleotides derived from salmon DNA fragments, purified for professional aesthetic use.

Vehicle: Isotonic buffer solution suitable for an injectable preparation.

The PN class is used in aesthetic settings because these fragments can interact with dermal fibroblasts and support extracellular matrix activity. This mechanism is relevant to skin elasticity, hydration balance, and texture-focused treatment goals. Claims about expected outcomes should be framed conservatively and documented according to clinic policy.

Because Rejuran I is not a hyaluronic acid volumizer, clinics should avoid positioning it as the same service as tear-trough filler. It may complement filler strategies in carefully staged plans, but product selection depends on anatomy, risk tolerance, injector preference, and the reason for under-eye hollowing or skin laxity.

Rejuran I Compared With Fillers

Rejuran I and dermal fillers are used for different purposes. Rejuran I is a PN-based injectable used in skin-quality workflows, while many fillers provide contour, projection, or volume replacement through a gel implant effect. A clinic may use one, both, or neither depending on the assessment.

This distinction matters around the eyes because thin tissue can make product choice more visible. Fillers may be considered for selected tear-trough anatomy, but inappropriate placement or product selection can create swelling, contour irregularity, or discoloration. PN boosters are typically discussed when the goal is texture refinement, elasticity support, and maintenance rather than immediate structural correction.

Practices that offer broader PN services may also evaluate Rejuran HB or Rejuran Healer for different treatment priorities. Product choice should be based on labeled presentation, treatment area, viscosity, injector experience, and clinic protocol rather than brand familiarity alone.

Packaging, Storage, and Handling

The manufacturer supplies Rejuran I as 1 syringe x 1ml. Store the product according to the manufacturer label and protect it from conditions that could compromise sterility or stability. Do not use the syringe if the seal, packaging, label, or solution appearance raises concern.

Receiving teams should record lot number, expiration date, and quantity on arrival. For multi-room practices, assigning units to treatment trays only when needed can reduce handling errors and support stock rotation. Use a first-expiry, first-out approach when it aligns with facility inventory policy.

We support professional logistics with temperature-controlled handling when required and tracked US delivery. Clinics should plan reorder timing around scheduled under-eye appointments, staff availability, and any internal receiving procedures needed before products move into clinical storage.

Safety, Contraindications, and Precautions

Rejuran I should be administered only by trained healthcare professionals familiar with periocular anatomy and injectable complication management. The eye area carries specific risks because vessels, thin skin, and lymphatic sensitivity can affect swelling, bruising, and visible placement outcomes.

Common injection-related effects may include temporary redness, swelling, tenderness, pinpoint bleeding, bruising, or small papules at placement sites. Clinics should provide aftercare instructions consistent with their protocols and advise patients when to report unusual pain, visual symptoms, progressive swelling, infection signs, or symptoms that do not follow the expected recovery pattern.

Contraindication screening and treatment timing should include active infection or inflammation in the treatment area, known hypersensitivity concerns, recent procedures, anticoagulant use considerations, pregnancy or lactation policies, autoimmune or wound-healing concerns, and any medical factors relevant to injectable procedures. The injector should decide whether to proceed, defer, or choose another approach.

For safe injectable practice, clinics should maintain aseptic technique, anatomy-aware placement, appropriate emergency procedures, and clear documentation. The FDA’s safe injection materials are intended for general injection safety principles; product-specific technique should come from professional training and manufacturer information.

Documentation and Staff Workflow

Rejuran I works best in clinics that separate consultation, consent, treatment mapping, and post-care documentation. Staff should document the indication for use, treatment area, syringe lot, expiration date, quantity used, injection method, injector name, and any immediate observations.

Front-desk and consultation teams should avoid presenting PN injectables as a universal replacement for fillers, surgery, or medical eye-area diagnosis. Clear language helps patients understand that Rejuran I is used for skin-quality support in professional aesthetic care, not for every cause of under-eye darkness, bags, or hollowing.

Quick tip: Keep Rejuran I in a dedicated periocular tray checklist so staff can verify syringe, expiry, consent, needle or cannula choice, and aftercare materials before the appointment begins.

Comparable PN and Skin-Quality Products

Clinics that stock Rejuran I may also evaluate other PN-based or skin-quality injectables for different treatment areas and viscosity preferences. Plinest Eye is a comparable eye-area product within the professional skin-quality category, while Plinest and Plinest One may be considered for broader protocol planning.

For teams developing internal education, Plinest injection clinical content can support general understanding of polynucleotide-style dermal repair positioning. Nucleofill Medium clinical content may also help teams compare how adjacent regenerative injectables are discussed in aesthetic practice.

Comparable products should not be substituted automatically. Confirm treatment area, pack presentation, handling instructions, injector familiarity, and clinic policy before changing a scheduled product. If a preferred item is not suitable for a case, the injector should reassess the treatment goal rather than making a brand-only swap.

Access, Availability, and Substitutions

Supply can vary by lot and manufacturer allocation. When substitution is needed, choose an alternative only after confirming the treatment area, product class, viscosity, syringe size, injector preference, and patient selection criteria. A PN eye booster may not be interchangeable with a broader face booster or a filler product.

For larger aesthetic programs, browsing skin booster education can help staff align product categories with service menus, consultation language, and training priorities. Keep all product claims within the evidence and instructions available to your clinic.

Authoritative Sources

• Rejuran official manufacturer information
• Peer-reviewed discussion of polynucleotides in aesthetic medicine
• CDC injection safety guidance for healthcare providers

Close

Ready to order? Choose your quantity above, or call 1-800-630-9757 to talk to our customer service team.

This content is for informational purposes only and is not a substitute for professional medical advice.